deltatrials
Completed PHASE3 NCT00002320

A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past

A Randomized, Double-Blind Multicenter Trial to Compare the Safety and Efficacy of Lamivudine (3TC; GR109714X) Monotherapy Versus Zidovudine (AZT) Monotherapy Versus 3TC Administered With AZT in the Treatment of HIV-1 Infected Patients Who Are AZT Naive (< 4 Weeks) With CD4 Cell Counts of 200-500 Cells/mm3

Sponsor: Glaxo Wellcome

Conditions HIV Infections
Interventions Lamivudine Zidovudine
Updated 5 times since 2017 Last updated: Dec 8, 2005

A PHASE3 clinical study on HIV Infections, this trial is completed. The trial is conducted by Glaxo Wellcome and has accumulated 5 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Glaxo Wellcome
Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States, Austin, United States, Brookline, United States, Chapel Hill, United States, Chicago, United States, Dallas, United States, Los Angeles, United States, Milwaukee, United States, Montreal, Canada, New Orleans, United States and 12 more location s